Literature DB >> 11829341

Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis.

Jerome R Wujek1, Carl Bjartmar, Edward Richer, Richard M Ransohoff, Min Yu, Vincent K Tuohy, Bruce D Trapp.   

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS). Most patients undergo an initial relapsing-remitting (RR-MS) course that transforms into a relentless neurodegenerative disorder, termed secondary progressive (SP)-MS. Reversible inflammation and demyelination account readily for the pattern of RR-MS but provide an unsatisfactory explanation for irrevocable decline in SP-MS. Axon loss is thought to be responsible for progressive, non-remitting neurological disability during SP-MS. There is considerable potential for neuroprotective therapies in MS, but their application awaits animal models in which axonal loss correlates with permanent neurological disability. In this report, we describe quantitative immunohistochemical methods that correlate inflammation and axonal loss with neurological disability in chronic-relapsing experimental autoimmune encephalomyelitis (EAE). At first attack, CNS inflammation, but not axon loss, correlated with the degree of neurological disability. In contrast, fixed neurological impairment in chronic EAE correlated with axon loss that, in turn, correlated with the number of symptomatic attacks. As proposed for MS, these observations imply a causal relationship between inflammation, axon loss, and irreversible neurological disability. This chronic-relapsing EAE model provides an excellent platform for 2 critical objectives: investigating mechanisms of axon loss and evaluating efficacy of neuroprotective therapies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11829341     DOI: 10.1093/jnen/61.1.23

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  69 in total

Review 1.  CXCL12 in control of neuroinflammation.

Authors:  Miljana Momcilović; Marija Mostarica-Stojković; Djordje Miljković
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

Review 2.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Prog Neurobiol       Date:  2010-10-12       Impact factor: 11.685

Review 3.  Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.

Authors:  Kelly A Chamberlain; Sonia E Nanescu; Konstantina Psachoulia; Jeffrey K Huang
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

4.  Estrogen mediates neuroprotection and anti-inflammatory effects during EAE through ERα signaling on astrocytes but not through ERβ signaling on astrocytes or neurons.

Authors:  Rory D Spence; Amy J Wisdom; Yuan Cao; Haley M Hill; Chandler R L Mongerson; Briana Stapornkul; Noriko Itoh; Michael V Sofroniew; Rhonda R Voskuhl
Journal:  J Neurosci       Date:  2013-06-26       Impact factor: 6.167

5.  Genetic inactivation of the p66 isoform of ShcA is neuroprotective in a murine model of multiple sclerosis.

Authors:  Kimmy G Su; Costanza Savino; Gail Marracci; Priya Chaudhary; Xiaolin Yu; Brooke Morris; Danielle Galipeau; Marco Giorgio; Michael Forte; Dennis Bourdette
Journal:  Eur J Neurosci       Date:  2012-01-25       Impact factor: 3.386

Review 6.  Interaction between the immune and central nervous systems.

Authors:  John H Russell
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 7.  IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease.

Authors:  Jarod Zepp; Ling Wu; Xiaoxia Li
Journal:  Trends Immunol       Date:  2011-04-12       Impact factor: 16.687

Review 8.  Review: Mitochondria and disease progression in multiple sclerosis.

Authors:  D Mahad; H Lassmann; D Turnbull
Journal:  Neuropathol Appl Neurobiol       Date:  2008-12       Impact factor: 8.090

9.  Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation.

Authors:  Roberta Brambilla; Trikaldarshi Persaud; Xianchen Hu; Shaffiat Karmally; Valery I Shestopalov; Galina Dvoriantchikova; Dmitry Ivanov; Lubov Nathanson; Scott R Barnum; John R Bethea
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

10.  Absence of the cellular prion protein exacerbates and prolongs neuroinflammation in experimental autoimmune encephalomyelitis.

Authors:  Shigeki Tsutsui; Jennifer N Hahn; Trina A Johnson; Zenobia Ali; Frank R Jirik
Journal:  Am J Pathol       Date:  2008-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.